(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Merck Foundation Fashion Awards 2023 Winners Announced to Acknowledge their Work to Empower Infertile Women and Support Girl ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Merck KGaA is in advanced negotiations to acquire U.S. biotech firm SpringWorks Therapeutics. While a deal isn't finalized, SpringWorks' share value surged following the talks. This acquisition could ...